• Ozge Ozgun, OzturkSeda DumanSDDepartment of Pathology, Kocaeli University School of Medicine, Kocaeli, Turkey., Cigdem Vural, KefeliAysegul UcuncuAUDepartment of Radiation Oncology, Kocaeli University School of Medicine, Kocaeli, Turkey., Sibel Balci, Devrim Cabuk, Kazim Uygun, and Umut Kefeli.
• Department of Internal Medicine, Kocaeli University School of Medicine, Kocaeli, Turkey.
• J. Investig. Med. 2024 Dec 1; 72 (8): 848856848-856.

AbstractThe A disintegrin and metalloprotease (ADAM) family is involved in many vital cellular events, from proliferation to migration, and accumulated evidence suggests its increased expression in malignant tumors. In this study, we investigated ADAM17 expression in non-small cell lung cancer (NSCLC) and its relationship with clinicopathological factors and survival. Immunohistochemical staining of ADAM expression was performed in 108 patients with NSCLC and in 54 control cases with no known malignant diagnosis. Association between ADAM17 expression, clinicopathological factors, and survival were analyzed. The Kaplan-Meier method was used for survival analysis. ADAM17 was lowly expressed in 89 (82.4%) and highly expressed in 19 (17.6%) of the patients with NSCLC. In univariate analysis, high ADAM17 expression, lymphovascular invasion, stage, and treatment response significantly affected progression-free survival (PFS) and overall survival (OS) (p < 0.05). Multivariate analysis also showed that high ADAM17 expression, lymphovascular invasion, stage, and treatment response were important prognostic factors for PFS and OS (p < 0.05). Our study revealed that high ADAM17 expression significantly associated with OS and PFS in patients with NSCLC. ADAM17 may potentially be the area of a new targeted treatment strategy in NSCLC. Thus, routine evaluation of ADAM17 expression in patients with NSCLC may be a future consideration.

27 keywords...

hide…